Last reviewed · How we verify
Amlodipine/Olmesartan
Amlodipine relaxes blood vessels by blocking calcium channels, while olmesartan blocks angiotensin II receptors to reduce vasoconstriction and lower blood pressure.
Amlodipine relaxes blood vessels by blocking calcium channels, while olmesartan blocks angiotensin II receptors to reduce vasoconstriction and lower blood pressure. Used for Hypertension.
At a glance
| Generic name | Amlodipine/Olmesartan |
|---|---|
| Sponsor | Radboud University Medical Center |
| Drug class | Calcium channel blocker / Angiotensin II receptor blocker combination |
| Target | L-type calcium channels (amlodipine); AT1 angiotensin II receptor (olmesartan) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Amlodipine is a dihydropyridine calcium channel blocker that inhibits L-type calcium channels in vascular smooth muscle, causing vasodilation. Olmesartan is an angiotensin II receptor blocker (ARB) that antagonizes AT1 receptors, preventing angiotensin II-mediated vasoconstriction and aldosterone release. Together, these complementary mechanisms provide additive antihypertensive effects.
Approved indications
- Hypertension
Common side effects
- Peripheral edema
- Headache
- Dizziness
- Fatigue
- Hyperkalemia
Key clinical trials
- Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study
- Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (PHASE2)
- Reduction Efficacy of OLOMAX for Blood Pressure and Low-density Lipoprotein Cholesterol in Hypertensive Patients With Dyslipidemia
- Impact of Antihypertensive Therapy on Recurrence Risk of Ovarian Cancer for Bevacizumab-associated Hypertension
- Clinical Trial to Evaluate the Efficacy and Safety of OLOMAX Tab (PHASE4)
- Multi-Omics to Predict the Blood Pressure Response to Antihypertensives (PHASE4)
- Optimal Medical Treatment of Difficult-to-treat Hypertension (PHASE4)
- Effect of Olmesartan on Angiotensin(1-7) Levels and Vascular Functions in Diabetes and Hypertension (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Amlodipine/Olmesartan CI brief — competitive landscape report
- Amlodipine/Olmesartan updates RSS · CI watch RSS
- Radboud University Medical Center portfolio CI